We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.50 | 16.00 | 17.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 5.81 | 15.05M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/11/2016 08:32 | Still think we'll see 90p before we see 100p ;) | owenmo | |
08/11/2016 07:00 | INFORMATION ABOUT US www.slimfast.co.uk is a site operated by KSF Acquisition UK Limited (We). We are registered in England and Wales under company number 09112415 and have our registered office at 3, Queen's Square, Ascot Business Park, Lyndhurst Road, Ascot, SL5 9FE, UK. Our VAT number is GB196257568. - See more at: | mirandaj | |
08/11/2016 01:01 | Followed Someuwin's link, I found the following on the site. I might be way off the mark but this sounds like it could be us.. http://www.nizo.com/ | 1bokke | |
07/11/2016 22:06 | Yes - I wasn't aware of NIZO working on skin microbiome product development. But this link shows they're all over it like...er a rash: | someuwin | |
07/11/2016 20:56 | Thanks for clearing that up, mouse. I hadn't seen the link. I don't ever recall NIZO being linked with Skinbiotix - I had always had NIZO down as sugars related. Risky - I have sang the same tune for some time, since GoFigure was launched, c12 months ahead of my expectations and I don't recall anyone else expecting it any earlier. I have to say though - I did not expect today's price drop. 1-2p perhaps. | elrico | |
07/11/2016 19:45 | The same Nizo logo was shown on the same chart in the year end accounts on page 11 hxxp://www.optibioti Accounts were published back in April. Nothing has changed on the chart since then. | mouse20 | |
07/11/2016 19:18 | I think Tom winnifreth has played a major part in certain investors disappointments in terms of expectations. Remember he was stating a massive deal with supposedly png was going to happen a month after the invention had been clinically validated. I've been in from near the start and my expectations have been more than met so far. The dsm deal is a concrete deal that will lead to revenues in the not so distant future. The fact we have these deals in place so early is excellent for such an early stage company. Try finding another company on AIM to achieve so much within 2 years of listing | riskybusiness1 | |
07/11/2016 19:05 | owenmo - It is my opinion SOH released the 'commercial update' RNS in the last week of October to offer the market and shareholders some comfort that things are progressing and that we should expect deals in the new year rather than this month. Who knows why deals have yet to materialise; the last thing we need this month is a RNS confirming so! | mazzstar | |
07/11/2016 18:45 | The Cleveland Clinic observations are most welcome; I would say, however, and who would argue, that it behoves SOH, in light of earlier-in-the-year stated aspirations, to deliver something concrete in November or otherwise offer comfort as to why expectation hasn't as yet materialised. | owenmo | |
07/11/2016 18:39 | Someuwin - I don't ever recall NIZO ever being mentioned in the same sentence as Skinbiotix. NIZO appears to be linked to Skinbiotix and Slimbiome....this is new, is it not. I guess this was what you were alluding in 17218. | elrico | |
07/11/2016 18:26 | The Cleveland clinic are renowned globally for their expertise on innovations within the health sector. Over 200 different innovations were voted upon by top academics and researchers who chose the microbiome as no 1 future game changer in health. They don't have shares in opti before anyone on here starts calling them mega bulls. I remember soh stating last year that though many media sources were saying 2016 to be the year of the microbiome he thought this was actually too early stating 2017 - 2018 as more likely. Obviously well in line with this recent Cleveland report.The majority of the market does not realise what opti have got in their locker. To modulate the microbiome in a targeted way is unexplainably massive. The opportunities this presents are immense....Price hasn't performed this year at all, especially compared to the first year. Make no mistake however, the foundations are excellently positioned to exploit this transition within the health space. | riskybusiness1 | |
07/11/2016 16:09 | Microbiome cited to be 'most important healthcare innovation'The Cleveland Clinic claims that "the gut is a gold mine" in terms of unlocking mysteries about the human body, and has put it in the number one spot of its Top Ten Medical Innovations of 2017.Recent research has suggested that the microbiome can have a positive effect on anything from diabetes to heart conditions, right through to anxiety and stress.UK-listed OptiBiotix Health plc(LON:OPTI) echoes those sentiments."If you look at where we were two or three years ago we were trying to understand the microbiome," says its chief executive Stephen OHara."Now, we understand the potential health benefits and, from an OptiBiotix point of view, we have the tools to manipulate the microbiome to create those health benefits. Microbes which form the microbiome in our body make up 90% of the cells on our body and, even though they're invisible to the naked eye, are essential for our survival.OHara explains that in recent years, scientists have discovered that it is more beneficial to change these microbes than to try and change the human cells in our body.This is what OptiBiotix is focusing on and has been for a good few years now manipulating the microbiome to try and improve various health conditions."We'll have more [partnership deals] coming through as partners start to recognise the importance of the microbiome and the work that we're doing." | parob | |
07/11/2016 14:28 | Hi Mazz, I mentioned it earlier. If you look here hxxp://www.optibioti Its under the heading our products / commercial strategy. There's a little diagram there listing commercial partners and KSF are still there. | woodaldo | |
07/11/2016 14:25 | It is showing the Nizo brand under skinbiotix but unlike the others it doesn't show a concluded agreement. The gant chart under the our products section is where I saw it. | 1bokke | |
07/11/2016 14:04 | The web site also states 3 core technology platforms, so I suspect that excludes Skinbiotix as being a separate platform - just a diversification of an existing platform. So I think there is no global brand commercial partner for Skinbiotix. | mouse20 | |
07/11/2016 14:02 | someuwin, does the website say anything about KSF/Slimfast? Someone mentioned it's on there but I could not find it. | mazzstar | |
07/11/2016 13:32 | The new website includes this line... • Commercial partners in place for all platforms with global brands Have we been told about a commercial partner for SkinBiotix yet? | someuwin | |
07/11/2016 11:56 | This rise has paused for breath | bobdown2 | |
07/11/2016 11:40 | downtrend in chart resumed | onedayrodders | |
07/11/2016 11:37 | Anyways no more comments from me until positive commercial news or 2017 when I will sell. | john henry | |
07/11/2016 11:33 | Cholesterol data is old clearly soh did not present on this. It would have been on the breakthrough that came through July this year. Regarding the sugar platform. This overlaps the cholesterol data as it has the ability to significantly increase efficacy of our cholesterol strain. The market has no idea how massive this is. As Cleveland clinic writes this space will revolutionise health and be very lucrative for companies like opti. Opti have the ability to target the microbiome which no other company in this space has shown. This is becoming more mainstream by the day now which will educate the market on the opportunities that are increasing exponentially for opti. | riskybusiness1 | |
07/11/2016 11:31 | Back to 60p | sofuca | |
07/11/2016 11:29 | JH were you at the conference last week? | 1bokke | |
07/11/2016 11:16 | Joy joy we are not working in the pharma industry yet. | john henry |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions